The abstract is read at the publisher; the summary is JClub's.
Entinostat plus anti-PD-1 and anti-CTLA-4 rewires metastatic breast cancer tumor microenvironments, enabling responders to show increased CD8+ T cell–macrophage distances and stronger lymphoid activation.
- Why it matters: Metastatic breast cancer often resists immunotherapy through intrinsic immune suppression, so combination strategies are needed that broaden responses by targeting tumor microenvironment circuits.
- What they did: The study integrated theory with scRNA-seq subclustering and cell circuit analyses from murine breast-to-lung metastases, then corroborated findings using patient biopsies and blood with spatial proteomics and flow cytometry.
- The result: Responders to entinostat + nivolumab + ipilimumab had increased T cell and B cell activation, mature tertiary lymphoid structures, and higher immunoglobulin production; B cells were necessary in mice, and myeloid ICAM1 and IFNβ pathway inhibition partially matched CD8+ T cell effects.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.